Palvella Therapeutics, Inc (PVLA) Stock

NASDAQ: PVLAHealthcare company in the biotechnology industry, based in Wayne, PA.

Palvella Therapeutics stock price chart

PVLA interactive chart →

PVLA stock quote & key statistics

Palvella Therapeutics earnings per share

Income →
Earnings per share

Palvella Therapeutics revenue & net income

Income →
RevenueNet income

Palvella Therapeutics annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$0-$41.7M-$3.71
FY2024$0-$17.4M-$14.28
FY2023$0$18.7M-$22.81
FY2022$25.9M-$33.3M-$36.00
FY2021$31.4M-$45.7M-$56.80

Fiscal year ending December 31. Source: company filings via EODHD.

About Palvella Therapeutics, Inc

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.

It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.

Palvella Therapeutics stock FAQ

What is the Palvella Therapeutics stock ticker symbol?

Palvella Therapeutics, Inc trades on the NASDAQ under the ticker symbol PVLA.

What sector and industry is Palvella Therapeutics in?

Palvella Therapeutics, Inc is classified in the Healthcare sector, Biotechnology industry.

How many employees does Palvella Therapeutics have?

Palvella Therapeutics, Inc has about 29 full-time employees.

What were Palvella Therapeutics's revenue and earnings last fiscal year?

Palvella Therapeutics reported revenue of $0 and net income of -$41.7M in fiscal 2025, with earnings per share of -$3.71.

Is Palvella Therapeutics in the Russell 2000?

Yes. Palvella Therapeutics, Inc (PVLA) is a component of the Russell 2000, the benchmark index of U.S. small-cap stocks.

When did Palvella Therapeutics go public?

Palvella Therapeutics stock began trading on December 16, 2024.

Russell 2000 Biotechnology stocks

All Russell 2000 →